Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | CPN1 | P15169 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4160461 | 0.98 | CYP1A2 (0.52) | CYP1A2TDP1F2KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL538390 | 0.98 | CYP1A2 (0.52) | CYP1A2TDP1F2KDM4ESMN1; SMN2 | |
| SCHEMBL7234914 | 0.81 | F2 (0.71) | F2CPN1CPB2CHIAMAPK1 | |
| SCHEMBL1276509 | 0.81 | — | — | |
| SCHEMBL14407779 | 0.81 | CYP1A2 (0.77) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL860793 | 0.81 | CYP1A2 (0.77) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL37407 | 0.81 | — | — | |
| SCHEMBL3222967 | 0.79 | CYP1A2 (0.59) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| SCHEMBL20614505 | 0.79 | CYP1A2 (0.59) | CYP1A2TDP1KDM4ESMN1; SMN2PIK3CD | |
| Acetic Acid SCHEMBL5485844 | 0.78 | F2 (0.68) | TDP1F2CPN1CPB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581533-A2 | NOVEL BENZONAPHTHYRIDINES | ALTANA Pharma AG (DE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004018465-A9 | BENZONAPHTHYRIDINES WITH PDE 3/4 INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | claimed |
| WO-2004018465-A2 | BENZONAPHTHYRIDINES WITH PDE 3/4 INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | claimed |
| WO-2023125707-A1 | P38 MAPK/MK2 PATHWAY REGULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-8329906-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines | NYCOMED GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| EP-1899335-B1 | PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PF MEDICAMENT (FR) | 2010-05-19 | — | — | EP | disclosed |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-7585872-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2009-09-08 | — | — | US | disclosed |
| EP-1899335-A1 | PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20070167482-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors | ALTANA PHARMA AG (DE) | 2007-07-19 | — | — | US | disclosed |
| WO-2007003611-A1 | PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2007-01-11 | — | — | WO | disclosed |
| EP-1581533-A2 | NOVEL BENZONAPHTHYRIDINES | ALTANA Pharma AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004018465-A9 | BENZONAPHTHYRIDINES WITH PDE 3/4 INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| WO-2004018465-A2 | BENZONAPHTHYRIDINES WITH PDE 3/4 INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | CYP1A2 583/4885TDP1 1606/4885F2 4608/4885 |
| US-20070167482-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors | PDE4A, PDE3A, PDE4B | CYP1A2 483/4885TDP1 48/4885F2 4348/4885 |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | PDE4A, PDE4B, PDE4C | CYP1A2 1387/4885TDP1 27/4885F2 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.